The deadline to submit an abstract for short talk consideration has passed.  For any questions or issues, please email info@keystonesymposia.org.

Drug discovery is undergoing a revolution that moves away from occupancy driven pharmacology to proximity based therapeutics that take advantage of event driven pharmacology. Induced proximity medicines or multi-specifics mobilize a cell’s natural biological mechanisms to tackle disease causing proteins through bringing together effectors and targets. Proximity based therapeutics have the potential to unlock new target space and make significant inroads to drug the “undruggable” genome. This conference will focus on understanding the opportunities and challenges in this exciting new area.

This meeting will concentrate on 4 key areas:

1) Controlling Post-Translational Modifications by Induced Proximity;

2) Emerging Proximity Biology for Target Degradation;

3) Stabilizing Protein-Protein Interactions with Molecular Glues;

4) Predicting and Discovering Ternary Complexes.

We will bring together interdisciplinary groups of scientists, including biologists and chemists, from both academic and industry to explore the latest findings in this field and accelerate its growth. Importantly, this meeting will be held jointly with the Keystone Symposium on Targeted Protein Degradation, to leverage the synergy between these two fields in terms of translating basic science into therapeutic potential.

Meeting organizers Michelle Arkin from the University of California, San Francisco, and Ryan Potts, from Amgen, Inc. about why you should attend this meeting in the video below: